Oncology Institute Stock Analysis
| TOI Stock | USD 0.15 0.01 6.25% |
Oncology Institute is undervalued with Real Value of 0.74 and Target Price of 2.5. The main objective of Oncology Institute stock analysis is to determine its intrinsic value, which is an estimate of what Oncology Institute is worth, separate from its market price. There are two main types of Oncology Institute's stock analysis: fundamental analysis and technical analysis.
The Oncology Institute stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Oncology Institute's ongoing operational relationships across important fundamental and technical indicators.
Oncology |
Oncology Stock Analysis Notes
About 20.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.74. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Oncology Institute has Price/Earnings (P/E) ratio of 190.67. The entity recorded a loss per share of 0.77. The firm had not issued any dividends in recent years. The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California. Oncology Institute operates under Medical Care Facilities classification in the United States and is traded on NASDAQ Exchange. It employs 658 people. To find out more about Oncology Institute contact Bradford Hively at 562 735 3226 or learn more at https://theoncologyinstitute.com.Oncology Institute Quarterly Total Revenue |
|
Oncology Institute Investment Alerts
| Oncology Institute generated a negative expected return over the last 90 days | |
| Oncology Institute has high historical volatility and very poor performance | |
| Oncology Institute has some characteristics of a very speculative penny stock | |
| Oncology Institute has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 324.24 M. Reported Net Loss for the year was (83.07 M) with profit before taxes, overhead, and interest of 52.09 M. | |
| Oncology Institute has about 64.21 M in cash with (36.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 20.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Hively Brad of 44000 shares of Oncology Institute subject to Rule 16b-3 |
Oncology Institute Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Oncology Institute previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Oncology Largest EPS Surprises
Earnings surprises can significantly impact Oncology Institute's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-08-08 | 2023-06-30 | -0.17 | -0.19 | -0.02 | 11 | ||
2022-08-09 | 2022-06-30 | -0.11 | -0.09 | 0.02 | 18 | ||
2023-11-08 | 2023-09-30 | -0.13 | -0.19 | -0.06 | 46 |
Oncology Institute Thematic Classifications
In addition to having Oncology Institute stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | HealthcareUSA Equities from Healthcare industry as classified by Fama & French |
Oncology Stock Institutional Investors
| Shares | Freegulliver, Llc | 2024-09-30 | 188.2 K | Renaissance Technologies Corp | 2024-09-30 | 170 K | Millennium Management Llc | 2024-06-30 | 109.2 K | State Street Corp | 2024-06-30 | 101.3 K | Saba Capital Management, Lp | 2024-06-30 | 94.3 K | Citadel Advisors Llc | 2024-09-30 | 91.3 K | Fielder Capital Group Llc | 2024-09-30 | 70.2 K | Northern Trust Corp | 2024-09-30 | 64.9 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 58.7 K | Fmr Inc | 2024-09-30 | 4.7 M | Deerfield Management Co | 2024-09-30 | 3.4 M |
Oncology Market Capitalization
The company currently falls under 'Micro-Cap' category with a total capitalization of 11.45 M.Oncology Profitablity
The company has Net Profit Margin of (0.2) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.17) %, which entails that for every $100 of revenue, it lost $0.17.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.45) | (0.47) | |
| Return On Capital Employed | (0.44) | (0.46) | |
| Return On Assets | (0.40) | (0.38) | |
| Return On Equity | (1.46) | (1.38) |
Management Efficiency
Oncology Institute has Return on Asset of (0.1942) % which means that on every $100 spent on assets, it lost $0.1942. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.2559) %, meaning that it generated no profit with money invested by stockholders. Oncology Institute's management efficiency ratios could be used to measure how well Oncology Institute manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.47. The current Return On Capital Employed is estimated to decrease to -0.46. As of now, Oncology Institute's Asset Turnover is decreasing as compared to previous years.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.77 | 0.83 | |
| Tangible Book Value Per Share | 0.43 | 0.39 | |
| Enterprise Value Over EBITDA | (3.36) | (3.19) | |
| Price Book Value Ratio | 2.64 | 2.51 | |
| Enterprise Value Multiple | (3.36) | (3.19) | |
| Price Fair Value | 2.64 | 2.51 | |
| Enterprise Value | 236.6 M | 224.8 M |
The management team at Oncology Institute has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Operating Margin (0.17) | Profit Margin (0.20) | Beta 0.616 | Return On Assets (0.19) | Return On Equity (1.26) |
Technical Drivers
As of the 26th of November, Oncology Institute holds the Variance of 50.77, coefficient of variation of (652.05), and Risk Adjusted Performance of (0.11). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Oncology Institute, as well as the relationship between them.Oncology Institute Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Oncology Institute middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Oncology Institute. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Oncology Institute Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Oncology Institute insiders, such as employees or executives, is commonly permitted as long as it does not rely on Oncology Institute's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Oncology Institute insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Oncology Institute Outstanding Bonds
Oncology Institute issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Oncology Institute uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Oncology bonds can be classified according to their maturity, which is the date when Oncology Institute has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| US68233JBV52 Corp BondUS68233JBV52 | View | |
| US68233JBU79 Corp BondUS68233JBU79 | View | |
| US68233JBR41 Corp BondUS68233JBR41 | View | |
| US68233JBP84 Corp BondUS68233JBP84 | View | |
| ONCOR ELEC DELIVERY Corp BondUS68233JBG85 | View | |
| ONCOR ELEC DELIVERY Corp BondUS68233JBH68 | View | |
| US68233JBD54 Corp BondUS68233JBD54 | View |
Oncology Institute Predictive Daily Indicators
Oncology Institute intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Oncology Institute stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Oncology Institute Forecast Models
Oncology Institute's time-series forecasting models are one of many Oncology Institute's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Oncology Institute's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Oncology Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Oncology Institute prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Oncology shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Oncology Institute. By using and applying Oncology Stock analysis, traders can create a robust methodology for identifying Oncology entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (0.26) | (0.24) | |
| Operating Profit Margin | (0.24) | (0.25) | |
| Net Loss | (0.26) | (0.24) | |
| Gross Profit Margin | 0.18 | 0.22 |
Current Oncology Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Oncology analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Oncology analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 2.5 | Strong Buy | 1 | Odds |
Most Oncology analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Oncology stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Oncology Institute, talking to its executives and customers, or listening to Oncology conference calls.
Oncology Stock Analysis Indicators
Oncology Institute stock analysis indicators help investors evaluate how Oncology Institute stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Oncology Institute shares will generate the highest return on investment. By understating and applying Oncology Institute stock analysis, traders can identify Oncology Institute position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 14 M | |
| Long Term Debt | 86.8 M | |
| Common Stock Shares Outstanding | 73.7 M | |
| Total Stockholder Equity | 57 M | |
| Tax Provision | -89 K | |
| Property Plant And Equipment Net | 40.1 M | |
| Cash And Short Term Investments | 82.9 M | |
| Cash | 33.5 M | |
| Accounts Payable | 14.4 M | |
| Net Debt | 86.2 M | |
| 50 Day M A | 0.2905 | |
| Total Current Liabilities | 34.8 M | |
| Other Operating Expenses | 401.3 M | |
| Non Current Assets Total | 65.7 M | |
| Non Currrent Assets Other | 561 K | |
| Stock Based Compensation | 17.8 M |
Complementary Tools for Oncology Stock analysis
When running Oncology Institute's price analysis, check to measure Oncology Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncology Institute is operating at the current time. Most of Oncology Institute's value examination focuses on studying past and present price action to predict the probability of Oncology Institute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncology Institute's price. Additionally, you may evaluate how the addition of Oncology Institute to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |